Article: Mind the Skills Gap
“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”
Article: Mind the Cell & Gene Gap
A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.
On-Demand Webinar: CQV Strategies that Increase Speed-to-Market for Gene Therapy
To successfully increase speed-to-market for gene therapies, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to gene therapy.
On-Demand Webinar: State of the Union for Advanced Medicines
We are in the midst of a therapeutic revolution. An H1 report released by Alliance for Regenerative Medicine (ARM) highlights a record-breaking year, with over 1,320 ongoing clinical trials worldwide and 1000+ therapeutic developers. As 2021 comes to an end, we are on track to expect the highest number of advanced therapy regulatory approvals, when compared to previous years.
On-Demand Webinar: CQV Strategies to Optimize Cell Therapy Manufacturing
When building a cell therapy manufacturing facility, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to cell therapy.
On-Demand Podcast: Foundations of Flexible Manufacturing
Is “flexible manufacturing” just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit? Business of Biotech Podcast: Episode 69, “Foundations of Flexible Manufacturing” features insights from Tony Khoury (EVP of Project Farma) and Brian Winstead (Senior Director, Facilities & Engineering at Sarepta Therapeutics) on what flexible manufacturing means, when it works and when it doesn’t.
On-Demand Podcast: The CDMO Capacity Crunch
Business of Biotech Podcast: Episode 68, “The CDMO Capacity Crunch” features insights from Anshul Mangal (President of Project Farma and Precision ADVANCE), Audrey Greenberg (Co-founder of Discovery Labs), and Sumit Verma (SVP, Commercial Manufacturing at Iovance) on CDMO buildouts, limited manufacturing space, and the expertise needed to meet timelines, satisfy investors, and drive competitive advantage.
On-Demand Interview: The Science Advisory Board – Precision ADVANCE Aims to Improve Patient Access to Cell and Gene Therapy
Anshul Mangal (President of Project Farma and Precision ADVANCE) and Phil Cyr (SVP, Customer Solutions at Precision Value & Health) sat down with Samantha Black (Editor in Chief at ScienceBoard) to discuss how Precision ADVANCE is driving innovation in the advanced therapy sector by improving patient access through interconnected services across the drug development spectrum.
CareTalk Podcast @ HLTH 2021 – Mark Clein Brings Precision to Medicine, But Not Quite at Warp Speed
Co-Founder and CEO of Precision Medicine Group Mark Clein sat down with CareTalk hosts John Driscoll and David E. Williams at HLTH Boston 2021 to discuss the game changing impact of precision medicine on treatments and patient outcomes.
On-Demand Webinar: Scaling Up a Gene Therapy Manufacturing Facility
Scaling up a gene therapy manufacturing facility is extremely complex and challenging. In this webinar, co-sponsored by Precision ADVANCE and Project Farma, a panel of industry experts discuss the strategies and challenges faced when building a cutting-edge gene therapy facility from the planning stages to build-out to operational readiness. They will also share key insights into their company’s approach to building these facilities and for mitigating risk under accelerated timelines.